Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLM60 in Relapsed Small-cell Lung Cancer
NCT04352413Phase 2Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome in small cell lung cancer (SCLC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jun 2020; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04352413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352413.